Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Status Recruiting

Clinical Trial Summary

For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.

Clinical Trial Description

Patients will receive intravenous hydration, acetaminophen and diphenhydramine hydrochloride (or appropriate alternative regimen) approximately 30 minutes prior to UCB infusion with doses adjusted for subject age and weight unless otherwise specified in the specific treatment protocol. Additional treatments will vary with the specific use of the UCB cells as specified in institutional review board (IRB)-approved disease-specific protocols at the University of Minnesota. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01451502
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Recruiting
Phase	N/A
Start date	October 20, 2011
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02497131` - Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients	Phase 2
Active, not recruiting	`NCT03264131` - BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma	Phase 2
Completed	`NCT03744676` - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)	Phase 2
Completed	`NCT02335242` - Sildenafil for the Treatment of Lymphatic Malformations	Phase 2
Completed	`NCT03135535` - Micro-mobile Foot Compression and Diabetic Foot	Phase 2
Active, not recruiting	`NCT05441943` - Lymphaticovenous Anastomosis as Treatment for Lymphedema	N/A
Recruiting	`NCT06267807` - Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders	N/A
Withdrawn	`NCT05431179` - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma	Phase 3
Recruiting	`NCT05731141` - A Prospective Natural History Study of Lymphatic Anomalies
Recruiting	`NCT03696784` - Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	Phase 1
Completed	`NCT03709407` - "Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study"	N/A
Active, not recruiting	`NCT02663297` - Administration of T Lymphocytes for Prevention of Relapse of Lymphomas	Phase 1
Completed	`NCT05683444` - Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial	Early Phase 1
Completed	`NCT02960841` - Effectiveness of Intracavitary Manual Lymphatic Drainage	Phase 4
Recruiting	`NCT05263583` - Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma	Phase 2
Terminated	`NCT02499627` - Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting	Phase 2
Recruiting	`NCT03373019` - Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Phase 2
Recruiting	`NCT03602157` - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL	Phase 1
Recruiting	`NCT02690545` - Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL	Phase 1/Phase 2
Completed	`NCT02744027` - Imaging of Lymphatic Anomalies	N/A